Our assessment
FitRx is the third storefront of a company this site already reviews twice. Its pages, its prices and its FAQ answers match its siblings' down to the wording, and its own terms-of-use page still greets visitors as customers of one of them. What it sells is real and its cash figures are published. What it is not is an independent seller.
One company, three shopfronts
The FDA's warning-letter records list three letters for the company behind this brand, one for each of three trading names. Two of those names are already reviewed on this site.
That matters if you are shopping around. Three entries that look like three companies are three doors into one, so trying the next one is not diversifying.
They are separate storefronts with separate letters, and they share an owner.
It calls you somebody else's patient
The homepage greets you by this brand's own name. The terms-of-use page greets you by a sibling brand's name, and both that page and the weight-loss FAQ link to reviews from that sibling's patients — nine mentions on the FAQ alone.
This is not a guess drawn from a shared design. It is the other brand's name, printed on the page that sets out the contract.
The prices, and which regime they belong to
A compounded semaglutide figure is published on the priced page with its condition attached: the rate holds when a three-month supply is bought. A compounded tirzepatide figure appears only in the FAQ.
The tile carrying the semaglutide figure is labeled as an insurance route, while the FAQ presents the same number as the option for people not using insurance. The page contradicts itself about which regime the figure belongs to.
The cheapest number on the page is not a price at all. It sits under an insurance heading, names four brand-name drugs, and is a copay that depends on an approved prior authorization. Never subtract it from a cash figure.
A membership exists, its first month is discounted, and its ongoing rate is never published.
Who is behind it
The terms name the operating company and the two clinical entities that employ the clinicians. The footer copyright uses a different corporate form of the same name, which is the sort of inconsistency worth noticing on a contract page.
No compounding pharmacy is named, no prescribing clinician is named, and no list of served states appears.
It carries an FDA warning letter issued in February 2026 over false and misleading claims and misbranding. That is a disclosure and it does not move this seller's position here.
FitRx's published pricing
Prices re-verified September 2026
| Medication | Price |
|---|---|
| MedicationSemaglutide (compounded) — as published | Price$151/mothe lowest rate, requiring prepayment for a three-month supply; the tile is labeled With Insurance, though the FAQ says this is the no-insurance rate |
| MedicationTirzepatide (compounded) — as published | Price$216/mothe lowest rate from the FAQ, depending on eligibility and treatment plan; no priced tile shows a tirzepatide figure directly |
Compare GLP may earn a commission when a reader signs up with a provider through a link on this site. 28 of the 420 providers reviewed here are paid partners today; the other 392 are not. See how this works.
See FitRx's current price →Who FitRx suits
Good fit if
- Readers already looking at its two sibling brands who want the third for comparison.
- Buyers who want somebody to work an insurance prior authorization first.
- People who will read a tile's heading before its number.
Look elsewhere if
- Anyone who thinks they are choosing an independent alternative to its siblings.
- Buyers who need the total monthly outlay, given the unpublished membership rate.
- Readers who need the pharmacy or the prescriber named.
- Anyone who needs their state confirmed before starting.
What stands out about FitRx
Strengths
- Publishes a compounded cash figure for both drugs and prints the quarterly-purchase condition on the same tile as the semaglutide number
- Explains the prior-authorization route at length and states that the coverage decision belongs to the insurer
- Names the operating company and the two clinical entities in its terms of use
- Prices its first month of membership rather than concealing that one exists
Trade-offs
- Received an FDA warning letter (No. 717987, issued February 2026) addressed to FitRX, LLC dba FitRx
- FitRX, LLC is the entity named in FDA warning letters concerning FitRx, AM Rx and Zealthy. These separate storefronts share the same legal entity.
- The terms and weight-loss FAQ refer to Zealthy patients, while the homepage refers to FitRx. Confirm which company is responsible for your treatment and account.
- Two CORPORATE FORMS: the terms of use govern use of "the FitRX, LLC website" while the footer copyright reads "© 2026 FitRx, Inc."
- Names no compounding pharmacy, no prescribing clinician and no list of states, and never publishes the ongoing membership rate
How this review was verified
- The homepage, privacy policy, terms of use, weight-loss page and weight-loss FAQ were read.
- The FDA's warning-letter records carry three letters for this operating company, under three trading names. Two of those brands are already reviewed here.
- A sibling brand's name appears nine times on this seller's weight-loss FAQ, and in the heading of its terms-of-use page.
- The semaglutide figure holds only when a three-month supply is bought. The tirzepatide figure appears only in the FAQ.
- The cheapest number on the priced page is an insurance copay conditional on an approved prior authorization, not a cash price.
- A membership is offered with a discounted first month. Its ongoing rate is not published.
Where FitRx ranks
FitRx qualifies for 3 of the 6 boards on this site. A board only ranks the providers that meet its own condition, so a missing board means FitRx does not publish what that board sorts on.
- Semaglutide — #252 of 334
- Tirzepatide — #242 of 319
- Cheapest Overall — #288 of 396
Compare FitRx directly
Compare GLP may earn a commission when a reader signs up with a provider through a link on this site. 28 of the 420 providers reviewed here are paid partners today; the other 392 are not. See how this works.
| Provider | Score | From/mo | Full review | Action |
|---|---|---|---|---|
| Belle Health | 10.0/10 | From/mo$109Advertised monthly equivalent for a twelve-month supply; not a verified monthly installment. Six-month rate $119, two-month rate $135, one-month rate $199. Confirm the upfront payment and refill schedule. | Full reviewRead the Belle Health review | Visit |
| Midi Health | 10.0/10 | From/mo$164for a 4-week supply, the lowest of four published dose tiers, including shipping | Full reviewRead the Midi Health review | Visit |
| altRx | 8.6/10 | From/mo$89/moadvertised monthly starting price for a multi-dose vial; confirm plan length and checkout total | Full reviewRead the altRx review | Visit |
Frequently asked questions
Is this an independent company?
No. The FDA's own records show the same legal entity behind this brand and two others already reviewed here.
Why does its terms page name another brand?
The site doesn't explain it. The sibling brand's name sits on the terms page, and nine times over on the weight-loss FAQ.
What does the compounded lane cost?
It publishes a figure for each drug, and the semaglutide one holds only when a three-month supply is bought.
Is the cheapest advertised number a price?
No. It sits under an insurance heading and is a copay reached through an approved prior authorization.
Does it have an FDA warning letter?
Yes, one issued in February 2026 over false and misleading claims and misbranding.
Ready to compare directly?
FitRx scores 2.9/10 on this site's rubric. Review the published prices and their conditions above, then confirm your total with the provider. Visiting its site does not commit you to treatment.
Compare GLP may earn a commission when a reader signs up with a provider through a link on this site. 28 of the 420 providers reviewed here are paid partners today; the other 392 are not. See how this works.
Visit FitRx →